AIM: Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9) and of a key pharmacologic target of vitamin K antagonists, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to coumarin derivatives. The role of these variants in fluindione response is unknown. Our aim was to assess whether genetic factors contribute to the variability in the response to fluindione. METHODS: Four hundred sixty-five patients with a venous thromboembolic event treated by fluindione for at least 3 months with a target international normalized ratio (INR) of 2.0 to 3.0 were studied. VKORC1, CYP2C9, CYP4F2 and EPHX1 genotypes were assessed. INR checks, fluindione doses and bleeding events were collected. RESULTS: VKORC1 genotype had a significant impact on early anticoagulation (INR value ≥2 after the first two intakes) (P < 0.0001), on the time required to reach a first INR within the therapeutic range (P < 0.0001) and on the time to obtain a first INR value > 4 (P= 0.0002). The average daily dose of fluindione during the first period of stability was significantly associated with the VKORC1 genotype: 19.8 mg (±5.5) for VKORC1 CC, 14.7mg (±6.2) for VKORC1 CT and 8.2mg (±2.5) for VKORC1 TT (P < 0.0001). CYP2C9, CYP4F2 and EPHX1 genotypes did not significantly influence the response to fluindione. CONCLUSIONS: VKORC1 genotype strongly affected anticoagulation induced by fluindione whereas CYP2C9, CYP4F2 and EPHX1 genotypes seemed less determining.
AIM: Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9) and of a key pharmacologic target of vitamin K antagonists, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to coumarin derivatives. The role of these variants in fluindione response is unknown. Our aim was to assess whether genetic factors contribute to the variability in the response to fluindione. METHODS: Four hundred sixty-five patients with a venous thromboembolic event treated by fluindione for at least 3 months with a target international normalized ratio (INR) of 2.0 to 3.0 were studied. VKORC1, CYP2C9, CYP4F2 and EPHX1 genotypes were assessed. INR checks, fluindione doses and bleeding events were collected. RESULTS:VKORC1 genotype had a significant impact on early anticoagulation (INR value ≥2 after the first two intakes) (P < 0.0001), on the time required to reach a first INR within the therapeutic range (P < 0.0001) and on the time to obtain a first INR value > 4 (P= 0.0002). The average daily dose of fluindione during the first period of stability was significantly associated with the VKORC1 genotype: 19.8 mg (±5.5) for VKORC1 CC, 14.7mg (±6.2) for VKORC1 CT and 8.2mg (±2.5) for VKORC1 TT (P < 0.0001). CYP2C9, CYP4F2 and EPHX1 genotypes did not significantly influence the response to fluindione. CONCLUSIONS:VKORC1 genotype strongly affected anticoagulation induced by fluindione whereas CYP2C9, CYP4F2 and EPHX1 genotypes seemed less determining.
Authors: Christina L Aquilante; Taimour Y Langaee; Larry M Lopez; Hossein N Yarandi; Jennifer S Tromberg; Dagmara Mohuczy; Katherine L Gaston; Cassandra D Waddell; Mark J Chirico; Julie A Johnson Journal: Clin Pharmacol Ther Date: 2006-02-28 Impact factor: 6.875
Authors: Mia Wadelius; Leslie Y Chen; Jonatan D Lindh; Niclas Eriksson; Mohammed J R Ghori; Suzannah Bumpstead; Lennart Holm; Ralph McGinnis; Anders Rane; Panos Deloukas Journal: Blood Date: 2008-06-23 Impact factor: 22.113
Authors: Gregory M Cooper; Julie A Johnson; Taimour Y Langaee; Hua Feng; Ian B Stanaway; Ute I Schwarz; Marylyn D Ritchie; C Michael Stein; Dan M Roden; Joshua D Smith; David L Veenstra; Allan E Rettie; Mark J Rieder Journal: Blood Date: 2008-06-05 Impact factor: 22.113
Authors: N A Limdi; G McGwin; J A Goldstein; T M Beasley; D K Arnett; B K Adler; M F Baird; R T Acton Journal: Clin Pharmacol Ther Date: 2007-07-25 Impact factor: 6.875
Authors: Ute I Schwarz; Marylyn D Ritchie; Yuki Bradford; Chun Li; Scott M Dudek; Amy Frye-Anderson; Richard B Kim; Dan M Roden; C Michael Stein Journal: N Engl J Med Date: 2008-03-06 Impact factor: 91.245
Authors: Michael D Caldwell; Tarif Awad; Julie A Johnson; Brian F Gage; Mat Falkowski; Paul Gardina; Jason Hubbard; Yaron Turpaz; Taimour Y Langaee; Charles Eby; Cristi R King; Amy Brower; John R Schmelzer; Ingrid Glurich; Humberto J Vidaillet; Steven H Yale; Kai Qi Zhang; Richard L Berg; James K Burmester Journal: Blood Date: 2008-02-04 Impact factor: 22.113
Authors: David A Flockhart; Dennis O'Kane; Marc S Williams; Michael S Watson; David A Flockhart; Brian Gage; Roy Gandolfi; Richard King; Elaine Lyon; Robert Nussbaum; Dennis O'Kane; Kevin Schulman; David Veenstra; Marc S Williams; Michael S Watson Journal: Genet Med Date: 2008-02 Impact factor: 8.822
Authors: Gonzalo Villapalos-García; Pablo Zubiaur; Rebeca Rivas-Durán; Pilar Campos-Norte; Cristina Arévalo-Román; Marta Fernández-Rico; Lucio García-Fraile Fraile; Paula Fernández-Campos; Paula Soria-Chacartegui; Sara Fernández de Córdoba-Oñate; Pablo Delgado-Wicke; Elena Fernández-Ruiz; Isidoro González-Álvaro; Jesús Sanz; Francisco Abad-Santos; Ignacio de Los Santos Journal: Life Sci Alliance Date: 2022-05-30